A woman's heart

@article{Ewer2009AWH,
  title={A woman's heart},
  author={M. Ewer and S. Glück},
  journal={Cancer},
  year={2009},
  volume={115}
}
Adjuvant therapy in postmenopausal women with breast cancer may contribute to the expression of underlying cardiovascular disease or expose the heart to additional toxicities. Tamoxifen remains an important component of endocrine therapy for breast cancer, although major clinical trials of the aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane suggest that these agents are more effective and better tolerated alternatives to tamoxifen. The AIs inhibit the conversion of androgens… Expand
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients
TLDR
In this article the available literature on cardiotoxicity of aromatase inhibitors is reviewed and some practical advice is provided to improve the cardiovascular safety profile of these drugs. Expand
Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
TLDR
Initial adjuvant treatment with an aromatase inhibitor (AI) is considered the standard of care for most postmenopausal women with node-positive and high-risk node-negative estrogen receptor (ER)-positive breast cancer and AIs are associated with significantly improved disease-free survival. Expand
Putting the Cardiovascular Safety of Aromatase Inhibitors in Patients with Early Breast Cancer into Perspective
TLDR
Overall, available data do not support a substantial risk of ischaemic CV events associated with adjuvant AI therapy; however, studies with longer follow-up are required to better characterize the CV profile of AIs. Expand
The development of endocrine therapy for women with breast cancer.
TLDR
The advances in endocrine therapies outlined here, coupled with advances in breast cancer management and diagnostics, will likely lead to more patient-tailored therapy, resulting in greater clinical benefits and more cost-effective treatment strategies. Expand
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane.
TLDR
Recent data to emerge primarily from the IES and Tamoxifen Exemestane Adjuvant Multicenter trials are considered and their implications for the role of exemestanes in the adjuvant treatment of breast cancer are considered. Expand
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
TLDR
In general, the evidence from clinical studies suggests that aromatase inhibitors are more effective than either tamoxifen or megestrol acetate as first- or second-line treatment in postmenopausal women with metastatic breast cancer. Expand
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
TLDR
Since adjuvant therapy for BC is potentially curative, emphasis must be placed on finding treatments combining maximum efficacy with the minimum of long-term side-effects in order to achieve survival with preserved quality of life. Expand
Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer
TLDR
A review will explore available results from AIs trials and will try to define their present role in the upfront adjuvant management of postmenopausal patients with breast cancer. Expand
Aromatase inhibitors: Role in postmenopausal breast cancer.
TLDR
This study highlights the aromatase inhibitors reported in the current literature as well as the recent advances in the management of breast cancer. Expand
Adjuvant aromatase inhibitor therapy: outcomes and safety.
TLDR
Results of ongoing safety analyses within some of the large AI trials should provide further insight into the long-term tolerability of AI therapy in the adjuvant setting. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
The balance between risks and benefits: Long-term use of aromatase inhibitors
TLDR
It can be concluded that the increased incidences of hypercholesterolemia and cardiovascular disease seen in patients taking an AI probably reflect the lack of the protective effects of tamoxifen in patients rather than a detrimental effect of the AI. Expand
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial
  • A. Monnier
  • Medicine
  • Expert review of anticancer therapy
  • 2006
TLDR
The FACE trial will not only provide an efficacy evaluation between these two aromatase inhibitors but also provide a valuable head-to-head comparison of the safety profiles of adjuvant letrozole and anastrozoles. Expand
The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study
TLDR
Exemestane appears to have a neutral effect on total cholesterol and HDL levels, unlike tamoxifen’s positive effect on LDL levels, which supports its potential usefulness in the adjuvant setting. Expand
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
TLDR
The present safety analysis, limited to cardiovascular AEs in BIG 1-98, documents a low overall incidence of cardiovascular AE, which differed between treatment arms. Expand
Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter
TLDR
A review of the current literature and updated trial data examines the effect both AIs and tamoxifen have on lipids and cardiovascular risk and highlights the importance of interpreting such data within the larger context of cardiovascular health in postmenopausal women. Expand
Cardiovascular Trials of Estrogen Replacement Therapy
TLDR
A review briefly describes the findings of the Heart and Estrogen/Progestin Replacement Study, the Estrogen Replacement and Atherosclerosis Trial, and other recently completed clinical trials that will radically alter contemporary understanding of the role of HRT for cardiovascular disease prevention. Expand
Meta-analysis of vascular and neoplastic events associated with tamoxifen
TLDR
This meta-analysis of randomized trials found tamoxifen use to be significantly associated with several neoplastic and vascular outcomes and considers balance of potential benefits and risks. Expand
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
TLDR
Switching to anastrozole after the first 2-3 years of treatment was confirmed to improve event-free and relapse-free survival of postmenopausal, node-positive, ER-positive early breast cancer patients already receiving adjuvant tamoxifen. Expand
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
TLDR
DFS, TTR, TTDR, and CLBC were improved significantly in the ITT and hormone-receptor-positive populations and long-term efficacy of anastrozole and tamoxifen is established. Expand
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.
TLDR
During 2 years of treatment, tamoxifen showed generally favorable effects on the lipid and lipoprotein profile of treated postmenopausal women, which may partially explain the decrease in adverse events and in mortality related to coronary heart disease seen in patients receiving adjuvant tamoxIFen treatment. Expand
...
1
2
3
4
5
...